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IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder involving virtually every 
organ with a risk of organ dysfunction. Despite recent studies regarding B cell and 
T cell compartments, the disease’s pathophysiology remains poorly understood. We 
examined and characterized subsets of circulating lymphocytes in untreated patients 
with active IgG4-RD. Twenty-eight consecutive patients with biopsy-proven IgG4-RD 
were included in a prospective, multicentric study. Lymphocytes’ subsets were ana-
lyzed by flow cytometry, with analysis of TH1/TH2/TH17, TFH cells, and cytokine release 
by peripheral blood mononuclear cells. Results were compared to healthy controls 
and to patients with primary Sjögren’s syndrome. Patients with IgG4-RD showed an 
increase of circulating T regulatory, TH2, TH17, and CD4+CXCR5+PD1+ TFH cell subsets. 
Accordingly, increased levels of IL-10 and IL-4 were measured in IgG-RD patients. TFH 
increase was characterized by the specific expansion of TFH2 (CCR6−CXCR3−), and 
to a lesser extent of T 17 (CCR6+ −FH CXCR3 ) cells. Interestingly, CD4+CXCR5+PD1+ TFH 
cells normalized under treatment. IgG4-RD is characterized by a shift of circulating 
T cells toward a TH2/TFH2 and TH17/TFH17 polarization. This immunological imbalance 
might be implicated in the disease’s pathophysiology. Treatment regimens targeting 
such T cells warrant further evaluation.
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inTrODUcTiOn
IgG4-related disease (IgG4-RD) is a newly recognized condition characterized by mass-forming 
lesions involving various tissues (1). The disease more frequently affects males over 50  years of 
age (2–4). The unifying finding of the disease is the pathological lesion characterized by dense 
lymphoplasmacytic infiltrates mainly consisting of CD4+ T cells and numerous IgG4+ plasma cells 
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associated with fibrosis (5). Tertiary germinal center formation 
is also frequently observed in diseased tissues.
Mikulicz’s disease, otherwise considered as a disease mani-
festation of primary Sjögren’s syndrome (pSS) (6) is also part of 
the spectrum of IgG4-RD. It has now been clearly demonstrated 
that despite common features shared by both diseases, clinical, 
biological, pathological, and immunohistological findings differ 
between pSS and IgG4-RD (7). Yet, in daily practice, pSS remains 
a frequent differential diagnosis of IgG4-RD.
Despite ongoing genetic and mechanistic studies, the patho-
genesis of IgG4-RD remains poorly understood. Rather than a 
vector of tissue damage, IgG4 is considered to be a marker of 
the disease. Yet, elevated levels of serum IgG4 have also been 
reported in other conditions, and approximately 30% of patients 
with biopsy-proven IgG4-RD have normal serum levels of IgG4 
(8). Hence, the identification of novel biomarkers is a timely topic 
in the field of IgG4-RD.
Besides studies regarding B cells and immunoglobulin biol-
ogy, careful attention is currently being paid on the role of T cells 
in the disease. Conflicting results have been reported regarding 
the polarization of T helper (TH) cells in IgG4-RD, especially 
in patients with pancreatic involvement and Mikulicz’s disease 
(9, 10). Because regulatory T cells (Treg) are a source of IL-10 
and TGF-β (i.e., key cytokines involved, respectively, in the 
differentiation of IgG4-producing B  cells and in the genesis of 
fibrosis), the roles of these cells have also been investigated in a 
few preliminary studies regarding IgG4-related hepatic and pan-
creatic involvements (11–13) More recently, T follicular helper 
cells (TFH), an important cell subset involved in the development 
of germinal centers as well as in antibody production, have also 
been studied in a small series of IgG4-RD patients (14) suggesting 
changes of this compartment in the disease. Yet, these results need 
to be confirmed in a new and larger cohort, including patients 
with other than salivary and lachrymal-restricted involvements, 
and with a more precise phenotypic definition of TFH subsets, 
especially concerning PD1 molecule expression.
In this study, we investigated circulating lymphocytes in 
untreated patients with IgG4-RD, with a focus on TH1/TH2/ 
TH17 balance and PD1+ TFH cells, and compared them to pSS 
patients.
PaTienTs anD MeThODs
study subjects
Patients with IgG4-RD were identified according to the 
Comprehensive Diagnosis Criteria (CDC) for IgG4-RD or to 
the International Consensus Diagnostic Criteria (ICDC) for 
autoimmune pancreatitis (15). Patients with pSS were identified 
according to the 2002 American-European Consensus Group cri-
teria. Patients with either IgG4-RD or pSS who received steroids 
or disease-modifying antirheumatic drugs within 3 months prior 
to study entry or who received rituximab within 6 months prior 
to enrollment were excluded from the study. Written informed 
consent was obtained from all patients with IgG4-RD or pSS as 
well as healthy controls (HC) prospectively included in the study. 
The study was approved by the local ethics committee [CPP 
Marseille I (Comité de Protection des Personnes Marseille I)].
immunophenotyping by Flow cytometry
Lymphocyte populations (total lymphocytes, T cells, CD4+ T cells, 
CD8+ T cells, B cells, and natural killer (NK) cells) were quanti-
fied with 6-Color BD Multitest and BD Trucount Technologies 
(Becton Dickinson, Le Pont de Claix, France) according to the 
manufacturer’s instructions.
MSL (Eurobio) density centrifugation was used to separate 
peripheral blood mononuclear cells (PBMCs) immediately after 
blood sample collection. The following antibodies were used: 
APC-H7 anti-CD45 or V500-anti-CD45, Amcyan-anti-CD3 
or APC-H7-anti-CD3, APC-H7-anti-CD4 or PE-anti-CD4, 
PerCP-Cy5.5-anti-CD8 or APC-anti-CD8, APC-H7-anti-CD20, 
V450-anti-CD45RA or PE-Cy5-anti-CD45RA, PE-Cy7-anti-
CD45RO, Alexa Fluor 488-anti-CXCR5, Alexa Fluor 647-anti-
PD1, PE-anti-CCR6, PE-Cy7-anti-CXCR3, APC-anti-CD25 
(BD Biosciences), PerCP-Cy5.5-anti-CD19, FITC-anti-CD62L 
(Beckman Coulter), or isotype-matched controls for 30 min.
TFH cells were defined as CD4+CD45RA−CXCR5+PD1+. 
Three TFH subsets were defined according to the expression 
of CCR6 and CXCR3, as follows: CCR6−CXCR3+ TFH1 cells, 
CCR6−CXCR3− TFH2 cells, and CCR6+CXCR3− TFH17 cells. 
Plasmablasts were defined as CD19+CD27highCD38high, naïve 
T cells as CD4+CD45RAhigh, memory T cells as CD4+CD45RO+, 
and NK cells as CD3−CD56+.
For intracellular markers, fixed and permeabilized cells were 
stained using Alexa Fluor 488-anti-FoxP3 (BD Biosciences) to 
analyze T regulatory cells defined as CD4+FoxP3+; PE-anti-IL-17, 
FITC-anti-IFNγ, and APC-anti-IL-4 (BD Bioscience) were used 
to characterize the functionally polarized CD4+ T  cell subsets 
after stimulation with PMA-ionomycin for 5 h according to the 
manufacturers’ instructions. The cells were washed with phos-
phate-buffered saline and then analyzed on a BD FACS Canto II.
analysis of cytokine Production
Levels of IL-4, IL-10, IL-17, and IFNγ in the supernatant of 
PBMCs following a 24-h stimulation with PMA-ionomycin were 
assessed using a multiplexed bead-based immunoassay (CBA® 
kit, BD Biosciences) following the manufacturers’ protocol.
statistical analysis
Continuous variables are shown as median ± SD. Multiple group 
comparisons were analyzed using the Kruskal–Wallis test and the 
Mann–Whitney U-test was used for comparison between two 
groups. Correlations were analyzed using Spearman’s correlation 
coefficient. The Wilcoxon test was used to analyze the changes in 
values over time. Statistical analyses were performed with Prism 
6 (GraphPad Software, San Diego, CA, USA).
For multiple testing, adjusted p-values were calculated using 
the false discovery rate procedure with the PROC MULTTEST 
statement (16). Statistical tests for multiple testing were made 
with the SAS 9.4 software.
resUlTs
Patients’ characteristics
Patients with IgG4-RD included in this study fulfilled the CDC 
(n = 27) or the ICDC criteria (n = 1). Clinical, biological, and 
Table 2 | Pathological characteristics of patients with igg4-rD.
P Tissue DlPi sF OP eo igg4/igg 
igg4/cD138a
igg4/hPF
1 Parotid x x 50%/IgG >50
2 RPF x x >50%/CD138 80
3 Meninges x x x 70%/CD138 60
4 Pancreas x 50%/CD138 45
5 Kidney x x ND 30
6 SMG x x x >40%/IgG 20
7 Lung x x ND 15
8 Pancreas, bile duct x x >40%/CD138 10
9 RPF x x 50%/CD138 60
10 Lymph node x x 80%/CD138 90
11 Kidney x x x x 50%/IgG ND
12 Kidney x x x 50%/CD138 30
13 SMG, pancreas x x x 90%/IgG ND
14 Mesenteritis x x 50%/CD138 30
15 Orbit x x x ND >10
16 Kidney x x >50%/CD138 40
17 Pancreas x ND 40
18 Lymph node x ND 100
19 Bile duct x x ND >10
20 Pancreas x x >40%/CD138 50
21 Bile duct x x x ND >10
22 Lymph node x x 80%/CD138 40
23 Lymph node x x >50%/IgG 30
24 Pancreas x x ND >100
25 Pancreas x x ND 80
26 Pancreas, skin x x >90%/CD138 >40
27 Liver x x x 0 0
28 SMG x x 50%/IgG ND
aIgG4 plasmocyte ratio is given either from IgG+ or total CD138+ plasmocytes.
DLPI, diffuse lymphoplasmacytic infiltrate; Eo, eosinophils; HPF, high power field; ND, 
not determined; OP, obliterative phlebitis; RPF, retroperitoneal fibrosis; SF, storiform 
fibrosis; SMG, submandibular gland.
Table 1 | general characteristics of patients with igg4-related disease 
(igg4-rD).
n g age Organ involvement igg4 
g/l
igg4-
rD ri
status
1 M 65 Parotid, LN 0.59 6 Relapse
2 M 66 RPF, LN, lung 4.74 12 First flare
3 M 66 Meninges, aorta 3.61 7 Relapse
4 M 57 Pancreas 6.3 6 First flare
5 M 78 Kidney, LN, lung, pancreas 21.9 13 Relapse
6 F 63 SMG, LN 1.56 9 First flare
7 F 80 RPF, lung, thyroid 0.49 6 First flare
8 M 47 RPF, pancreas, lung 1.34 2 Relapse
9 M 86 Lung, LN, RPF 15.7 10 Relapse
10 M 76 Bone, LN 27.5 9 First flare
11 M 66 RPF, lung, kidney 2.56 12 First flare
12 M 37 Kidney, lung, pancreas, prostate, 
testis, LN
18.5 15 Relapse
13 M 31 Orbit, lung, LN, pancreas, SMG 15.5 12 Relapse
14 M 80 Mesenteritis 3.16 4 First flare
15 F 39 Orbit 1.04 6 First flare
16 M 74 Kidney, pancreas, LN 3.66 12 Relapse
17 M 63 RPF 7.4 6 First flare
18 M 63 LN 10.9 6 First flare
19 M 52 Pancreas, LN, bile duct 10.2 9 Relapse
20 M 78 Pancreas 4.5 3 First flare
21 M 57 Bile duct 1.1 3 First flare
22 M 67 Lung, SMG, LN 5.84 9 First flare
23 M 82 Kidney, SMG, lung, LN 36.7 15 Relapse
24 M 43 LN, pancreas, bile duct 22.4 5 First flare
25 M 79 LN, pancreas 3.2 3 First flare
26 M 77 Pancreas, skin 16.4 3 First flare
27 F 46 Pancreas, liver, lung, LN 3,59 12 First flare
28 M 63 Dacryoadenitis, LN, pancreas 12,3 12 First flare
F, female; G, gender; LN, lymph nodes; M, male; n, number; RI, responder index; RPF, 
retroperitoneal fibrosis; SMG, submandibular glands.
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pathological characteristics of these patients are reported 
in Tables  1 and 2. Mean age was 63.6  ±  15, 57  ±  13, and 
59 ±  17.3  years in patients with IgG4-RD, pSS (n =  21), and 
HC (n = 28), respectively. Male gender was overrepresented in 
patients with IgG4-RD as compared to pSS and HC (85.5% versus 
23 and 57%).
IgG4 levels were >1.35  g/l (mean 7.9 ±  6.1  g/l) in 82% of 
patients with IgG4-RD, median IgE level was 627 ± 1,092 UI/l 
and median eosinophil count 443 ± 499 cells/μl (19% of patients 
had >500 cells/μl) in IgG4-RD patients. Most patients with 
IgG4-RD (67%) were analyzed at the first flare of the disease. 
Organ involvement at the time of analysis included lymph nodes 
(n = 17), lung (n = 10), pancreas (n = 8), retroperitoneal fibrosis 
(n = 5), kidney (n = 5), salivary glands (n = 4), orbit (n = 3), and 
bile ducts (n = 2), and 64% of patients with IgG4-RD presented 
with ≥2 organs involved (Table 1).
lymphocyte subsets in Patients with 
igg4-rD
Analysis of patients with IgG4-RD showed no difference in 
the number and proportion of CD4+, CD8+ T cell subsets, and 
NK  cells compared to HC (Figure  1A). Interestingly, both the 
number (1,685 ± 418 cells/μl versus 351 ± 66 cells/μl; p = 0.001) 
and proportion of circulating plasmablast cells were increased in 
patients with IgG4-RD compared to HC, although B cell counts 
were similar within the three groups (Figure 1B).
CD4+Foxp3+ Treg were significantly increased in patients with 
IgG4-RD compared to HC and pSS patients (71.11 ± 7.3 cells/μl 
versus 57 ± 6.8 and 46.8 ± 8.3 cells/μl; p = 0.01 and p = 0.02, 
respectively) (Figures  2A,B). As Treg cells produce IL-10, the 
ability of PBMCs to produce IL-10 was evaluated following PMA-
ionomycin stimulation. A significantly higher amount of IL-10 
was detected in supernatants of stimulated PBMCs from patients 
with IgG4-RD compared to HC and pSS patients (70.6 ± 29.1 pg/
ml versus 20.8 ± 3.8 and 24.2 ± 9.2 pg/ml; p = 0.009 and p = 0.03, 
respectively) (Figure 2C).
Th1, Th2, and Th17 cell Distribution in 
Patients with igg4-rD
To analyze the distribution of functionally polarized CD4+ T cell 
subsets in patients with IgG4-RD, PBMCs were stimulated for 5 h 
using PMA-ionomycin (Figures 3A,B). The percentage of IL-4-
producing CD4+ T cells (TH2) was significantly higher in patients 
with IgG4-RD compared to HC and pSS patients (3.4 ± 0.36% 
versus 1.5 ± 0.14 and 2.2 ± 0.5%; p < 0.0001 and p = 0.03, respec-
tively). In addition, IL-17+-producing CD4+ T cells (TH17) were 
significantly higher in patients with IgG4-RD compared to HC 
(1.0 ± 0.17% versus 0.7 ± 0.17%; p = 0.02) but not to patients with 
FigUre 2 | regulatory T cells (Treg) cells and il-10 release in igg4-related disease (igg4-rD) patients. A representative staining of CD4+FoxP3 Treg cells 
is shown (a). Peripheral blood Treg cells counts in IgG4-RD patients (blue lines), healthy controls (HC) (black lines), and Sjögren syndrome patients (orange lines) (b). 
IL-10 release by PBMC after PMA-ionomycin stimulation is shown in IgG4-RD patients (blue lines), HC (black lines), and Sjögren syndrome patients (orange lines) 
(c). Bars show the median and the 10th and 90th percentiles. If the Kruskal–Wallis test is significant, groupwise comparisons are performed by the Mann–Whitney 
U-test. p is considered significant when <0.05; *p < 0.05; **p < 0.01.
FigUre 1 | lymphocyte subsets in igg4-related disease (igg4-rD) patients. IgG4-RD patients (blue lines) are compared to healthy controls (black lines) and 
Sjögren syndrome patients (orange lines). Peripheral blood T, B, and NK cells counts are shown (a). A representative staining used to detect plasmablasts (upper 
panel) and their cell counts in the three groups (lower panel) are shown (b). Bars show the median and the 10th and 90th percentiles. If the Kruskal–Wallis test is 
significant, groupwise comparisons are performed by the Mann–Whitney U-test. p is considered significant when <0.05; *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001.
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pSS. Conversely, the proportion of TH1 IFNγ+ producing cells was 
similar in all three groups of patients.
cytokine secretion Profile in Patients  
with igg4-rD
In order to further confirm the trend toward a TH2/TH17 balance 
in IgG4-RD, PBMCs’ cytokines production following a 24-hour 
stimulation with PMA-ionomycin was measured using a multi-
plexed CBA assay. As shown in Figure 3C, higher levels of IL-4 
and IL-17 were detected in patients with IgG4-RD as compared 
to HC and pSS patients (82.4 ± 16.8 pg/ml versus 24.1 ± 5.6 and 
89.7 ± 48.1 pg/ml for IL-4; p < 0.0001 and p = 0.02, respectively; 
and 120.4 ± 65.4 pg/ml versus 15.5 ± 5.5 and 80 ± 49 pg/ml for 
IL-17; p = 0.006 and p = 0.01, respectively). No such difference 
was observed with levels of IFNγ.
cD4+cXcr5+PD1+ TFh are specifically 
increased in Patients with igg4-rD
The ectopic lymphoid structures found in tissues of patients 
with IgG4-RD led us to investigate for the presence of TFH 
FigUre 3 | Th1/Th2/Th17 profile and cytokine production in igg4-related disease (igg4-rD) patients. A representative staining showing interferon gamma 
(TH1 cells)-, IL-4 (TH2)-, and IL-17 (TH17)-producing CD4+ T cells without stimulation (upper dot-plots) or after PMA-ionomycin treatment (lower dot-plots) (a). 
Percentages of TH1, TH2, and TH17 cells after PMA-ionomycin stimulation in IgG4-RD patients (blue lines), healthy controls (HC) (black lines), and Sjögren syndrome 
patients (orange lines) (b). Cytokine secretion by PBMC after PMA-ionomycin stimulation in IgG4-RD patients (blue lines), HC (black lines), and Sjögren syndrome 
patients (orange lines) (c). Bars show the median and the 10th and 90th percentiles. If the Kruskal–Wallis test is significant, groupwise comparisons are performed 
by the Mann–Whitney U-test. p is considered significant when <0.05; *p < 0.05; **p < 0.01; ****p < 0.0001.
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cells in patients’ peripheral blood. Such cells were defined as 
CD4+CXCR5+CD45RA−PD1+ lymphocytes (Figure  4A). This 
subset was significantly increased in patients with IgG4-RD 
when compared to HC and pSS patients in both percentages 
(3.7 ±  0.3% versus 1.7 ±  0.1 and 2 ±  0.2%; p <  0.0001 and 
p = 0.001, respectively) and numbers (35.4 ± 4.8 cells/μl versus 
13.4 ± 0.9 and 13.9 ± 1.6 cells/μl; both p < 0.0001, respectively) 
(Figure  4B). We also evaluated PD1+ TFH cell number in 11 
IgG4-RD patients who were treated with steroids alone (n = 4), 
steroids plus azathioprine (n =  1), or steroids plus rituximab 
(n  =  6). Interestingly, disease remission in these treated 
IgG4-RD patients was associated with reduced circulating TFH 
cells (Figure  4C).
TFh2 and TFh17 are the Main T Follicular 
helper cells expanded in Patients with 
igg4-rD
As for T helper cells, TFH cells can be further classified into 
distinct subsets according to cell-surface chemokine receptor 
expression: TFH1 (CCR6−CXCR3+), TFH2 (CCR6−CXCR3−), 
and TFH17 (CCR6+CXCR3−) (Figure  5A). Among the 
CD4+CXCR5+PD1+ TFH cells, TFH2 cells were the main 
increased subset in patients with IgG4-RD compared to HC 
and pSS patients for both number and percentages (8.5 ± 1.6 
cells/μl versus 2.2 ± 0.2 and 2.2 ± 0.4 cells/μl; p < 0.0001 and 
p = 0.0004, respectively; and 44.2 ± 2.7% versus 33.2 ± 1.6 and 
35 ± 2.6%; p = 0.0003 and p = 0.005, respectively). The number 
of TFH17 cells was higher in patients with IgG4-RD as compared 
to HC and pSS patients (2.83 ±  0.6 cells/μl versus 1.4 ±  0.1 
and 1.3 ±  0.3 cells/μl; p =  0.03 and p =  0.06, respectively). 
Last, the proportion of TFH1 cells was decreased in patients 
with IgG4-RD as compared with HC and pSS patients (19 ± 1.9 
cells/μl versus 26.6 ±  1.4 and 27.2 ±  2.1 cells/μl; p =  0.002 
and p =  0.003, respectively) (Figure  5B).
DiscUssiOn
IgG4-related disease is characterized by tissue infiltration by 
numerous IgG4+ plasmocytes, increased numbers of circulating 
plasmablasts and elevated titers of both serum IgG4, IgE, as well 
as other IgG subclasses (2). B cell activation appears to be T cell-
dependent because activated B cells harbor enhanced somatic 
mutation, and relapses after rituximab (a B-cell-depleting 
agent) are characterized by the emergence of new plasmablast 
clones (17). T CD4+ cells are numerous in disease infiltrates 
and are thought to trigger B  cell polyclonal expansion and 
fibrosis. Prior studies regarding blood and/or tissue analysis of 
IgG4-RD patients suggest changes of T helper cells, Treg, and 
FigUre 4 | T follicular helper cells in igg4-related disease (igg4-rD) patients. Representative staining showing an expansion of CXCR5+PD1+ TFH cells in 
untreated patients with IgG4-RD compared to an healthy individual (a). CXCR5+PD1+ TFH cells percentage (left panel) and absolute numbers (right panel) are higher 
in IgG4-RD patients (blue lines) than in healthy controls (black lines) and Sjögren syndrome patients (orange lines) (b). Both TFH cells percentage (left panel) and 
absolute numbers (right panel) decrease after treatment in patients with IgG4-RD (c). Bars show the median and the 10th and 90th percentiles. If the Kruskal–Wallis 
test is significant, groupwise comparisons are performed by the Mann–Whitney U-test. p is considered significant when <0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001.
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more recently oligoclonal CD4+ effector/memory cytotoxic 
T lymphocytes (9–11, 18, 19).
Hence, we conducted a systematic analysis of lymphocyte 
subsets in untreated patients with IgG4-RD. Major T cell subsets, 
including memory and naïve T cells, NK, and B cells were normal 
in patients with IgG4-RD compared to HC. Concordant with 
previous reports, plasmablast cell counts were higher in patients 
with IgG4-RD as compared to HC (17). Albeit not reaching 
significance, plasmablast cells were also higher in patients with 
IgG4-RD as compared to pSS patients. Next, in line with a previ-
ous study, there was a clear trend toward an increase of circulating 
CD4+Foxp3+ Tregs in IgG4-RD patients, suggesting that in such 
patients Treg expansion is not restricted to diseased tissues (18). 
Treg were also shown to be increased in blood, without reaching 
significance, in an independent study (19). In IgG4-RD, Treg 
expansion might contribute to the genesis of fibrosis through 
TGF-β release and to the increase of IL-10 release by PBMCs. 
From that perspective, IgG4-RD is different than most autoim-
mune diseases where Treg are commonly decreased (20).
Over-production of TH2-related cytokines (IL-4, IL-13, and 
IL-5) in IgG4-RD tissues has previously been reported (11) 
and correlates with IgE and IgG4 class switch, blood eosino-
philia, and eosinophilic infiltrates that are common features 
of IgG4-RD (4, 11). Hence, and despite previous studies that 
provided conflicting results regarding the TH1/TH2 balance in 
PBMCs from IgG4-RD patients, it has been suggested that TH2 
cells might be key players in the disease’s pathophysiology (9, 
10). Yet, the central role of such cells is debated because IL-4 
production upon re-stimulation has been shown to be restricted 
to CD4+GATA3+ T cells in patients with known atopy, suggesting 
that the role of TH2 responses in IgG4-RD might be confounded 
by concomitant allergic disease (21). The present analysis of 
TH1, TH2, and TH17 cells in IgG4-RD showed an increase of both 
TH2 and TH17 cells. Interestingly, the increase of TH2 cells in 
the present study was not restricted to a unique organ involve-
ment. Moreover, only 4 out of 28 patients (16%) with IgG4-RD 
also complied with the definition of the European Academy 
of Allergy and Clinical Immunology for atopy (22). TH2 and 
TFH2 cell number, IgE levels, and eosinophil numbers were not 
significantly different between atopic and non-atopic patients 
(data not shown). Hence, according to our data, TH2 cell expan-
sion in IgG4-RD patients cannot be restricted only to patients 
with concomitant atopy. Next, the analysis of cytokine release by 
PBMCs upon stimulation were in line with these findings and 
showed that patients with IgG4-RD produced higher amounts 
of IL-4 but also of IL-10 and IL-17 as compared with HC and 
patients with pSS. Both TH2 and Treg are thought to contribute 
to IL-4 and IL-10 release, but we did not expect to report on 
both high IL-17 levels and elevated TH17 cells. Analysis of the 
co-expression of intracellular IL-17 and IL-4 after stimulation 
FigUre 5 | specific changes of T follicular helper subsets in igg4-related disease (igg4-rD) patients. (a) A representative staining showing TFH cells 
subsets defined according to the expression of CXCR3 and CCR6: TFH1 are CXCR3+CCR6− cells, TFH2 are CXCR3−CCR6− cells, and TFH17 are CXCR3−CCR6+ cells. 
(b) Percentage of T follicular helper subsets among total TFH cells (upper panel) and cell numbers (lower panel) of TFH1, TFH2, and TFH17 in the peripheral blood are 
shown for IgG4-RD patients (blue lines), healthy controls (black lines), and Sjögren syndrome patients (orange lines). Bars show the median and the 10th and 90th 
percentiles. If the Kruskal–Wallis test is significant, groupwise comparisons are performed by the Mann–Whitney U-test. p is considered significant when <0.05; 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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in CD4+T cells showed that double positive cells were extremely 
rare, and therefore that the source of both cytokines were dif-
ferentiated TH2 or TH17 cells (data not shown).
Extranodal germinal centers are often found in IgG4-RD 
tissues, and IgG4+ plasmablasts harbor somatic hypermutation 
(17), a process occurring during B cell differentiation in germinal 
centers. Because TFH are essential for germinal center forma-
tion and Ig class switch in humans and mice, they could be 
implicated in the pathogenesis of IgG4-RD (23). The circulating 
TFH compartment in human is heterogeneous based on PD1, 
CCR6, and CXCR3 expression (23, 24). Here, we show that 
the CD4+CXCR5+PD1+ TFH cells are specifically expanded in 
IgG4-RD. Interestingly, since only one patient presented with 
an increase of TFH after treatment with rituximab, expansion is 
reversible in patients with IgG4-RD that are efficiently treated. 
Expanded PD1+ TFH have been previously reported in human 
autoimmune diseases such as systemic lupus erythematosus, 
pSS, and juvenile dermatomyositis (25, 26). In the latter, both 
TFH2 and TFH17 are increased and correlate with plasmablast 
numbers and disease activity (26). In our analysis, CXCR5+PD1+ 
TFH cells were not expanded in untreated pSS patients but were 
expanded in IgG4-RD. TFH expansion was mostly related to the 
TFH2 CCR6−CXCR3− subset and to a lesser extent to the TFH17 
CCR6+CXCR3− subset. TFH2 and TFH17 cells have been shown 
to efficiently induce in  vitro naïve B  cells to proliferate and 
differentiate into plasmablasts and produce all IgG subclasses, 
in contrast to TFH 1 (25). TFH2 specifically produces IL-4, IL-5, 
and IL-13, which are important cytokines for the class switch-
ing to IgE and IgG4. The expansion of TFH 2 is consistent with 
pathological and biological abnormalities reported in IgG4-RD 
patients. Our study showed that TFH2 cell numbers correlated 
positively with serum IgG4 (r = 0.64; p = 0.0004), IL-4 (r = 0.55; 
p =  0.01), and IL-10 (r =  0.49; p =  0.03) (Table 3). Moreover, 
an increase of the CD4+CXCR5+CD45RA− TFH and TFH 2 cells 
in IgG4-RD has been reported in another series of 15 patients 
(14). However, PD1 expression was not analyzed. The specific 
expansion of CXCR5+PD1+ TFH observed in our study could 
be related to some unique functional properties inherent to 
IgG4-RD’s pathogenesis. Indeed, PD1+ TFH require less activation 
than PD1− TFH to differentiate into functional helpers and, by 
Table 3 | analysis of the correlation between TFh and TFh2 cell number 
and clinical or biological variables in patients with igg4-rD.
correlation between 
variables
r (spearman) p-Value adjusted p-value
TFH and IgG4-RI −0.15 0.52 0.71
TFH2 and IgG4-RI 0.2 0.36 0.62
TFH and number of OI −0.03 0.85 0.86
TFH2 and number of OI 0.14 0.48 0.70
TFH and IgG4 0.3 0.13 0.35
TFH2 and IgG4 0.64 0.0004 0.008
TFH2 and IgG1 0.21 0.31 0.62
TFH2 and eosinophils −0.04 0.86 0.86
TFH2 and IgE 0.24 0.33 0.62
TFH and plasmablast −0.03 0.20 0.48
TFH2 and plasmablast 0.37 0.1 0.32
TFH and IL-10 0.18 0.47 0.70
TFH2 and IL-10 0.49 0.03 0.14
TFH and IL-4 0.06 0.8 0.86
TFH2 and IL-4 0.55 0.01 0.09
TFH and IL-17 0.41 0.1 0.32
TFH17 and IL-17 0.62 0.004 0.04
TFH2 and IL-17 0.08 0.72 0.86
TFH1 and IFNγ 0.12 0.62 0.79
The cytokines listed in the variables column correspond to cytokines released from 
peripheral blood mononuclear cells following 24 h stimulation with PMA-ionomycin and 
measured using a multiplexed CBA assay.
Correlations were performed by analyzing TFH cell number/μl with other variables. p was 
considered significant by Spearman test when <0.05 (in bold). For multiple testing, 
adjusted p-values were calculated using the false discovery rate procedure.
IgG4-RI, IgG4 responder index; OI, organ involvement.
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opposition to PD1− TFH, PD1+ TFH express low levels of CCR7 
(24). The PD1+CCR7low TFH population is required for T cells to 
migrate into B cell follicles (27). Thus the specific expansion of 
PD1+ TFH in IgG4-RD could be an important trigger to B  cell 
activation, class switch, and plasmablast generation. Interestingly, 
it has been shown in rheumatoid arthritis that PD1+ TFH is main-
tained by plasmablasts by an IL-6-dependent positive feedback 
loop that should be investigated in IgG4-RD (28).
The findings reported in our study consist of correlations 
and causation of these T  cells changes in the pathophysiol-
ogy of IgG4-RD have to be confirmed by further functional 
studies. It has been recently shown in Japanese patients with 
predominant salivary and lachrymal glands involvement that 
CD4+CD45RA−CXCR5+CCR6−CXCR3− TFH2 cells were more 
efficient in inducing differentiation into plasmablasts and led 
to higher IgG4 production by autologous naïve B cells in active, 
untreated IgG4-RD patients than in HC (29), suggesting a func-
tional role of these cells in the disease. The same authors found 
in a previous study a correlation between the increased number 
of circulating TFH2 cells and the number of plasmablasts (14), 
which was not found in our study. Conversely it is also plausible 
that these T cells changes are secondary to yet other unknown 
factor(s) (e.g., a source of TGF-β) that drives T cell differentiation 
and IgG4 production. In this line, mast cells have recently been 
shown to express IL-4, IL-10, and TGF-β (30), as well as IL-13 (31) 
in IgG4-RD tissues, and these innate cells could contribute to the 
TH2/T regulatory cytokines orientation reported in the disease.
Major cytokines involved in the early TFH differentiation 
process from CD4+ T cells in human, including IL-12, IL-23, and 
TGF-β, are also supported by other STAT3-activating cytokines 
including IL-6, IL-21, and IL1-β (23). In human autoimmune 
diseases, both TH17 and TFH co-emerge and share a develop-
mental mechanism induced by TGF-β. It has been proposed 
that abundant expression of TGF-β in inflammatory sites in 
human autoimmune diseases (28), where tertiary lymphoid 
organs are often formed, contribute to the generation of TFH 
and TH17 cells (24). Hence, the expansion of these cells could be 
the consequence of an initial inflammatory process. In tissues, 
TH17-related molecules have been reported in salivary glands of 
patients with IgG4-RD, albeit at low levels (32). The site where 
the differentiation and expansion of TFH occurs in IgG4-RD is 
unknown, and no link has been established with IL-1β and TGF-β 
producing clonal expanded CD4+SLAMF7+ CTLs (19).
Interestingly, our results showed that PD1+ TFH cells were 
significantly decreased in patients with IgG4-RD who were 
treated with either steroids alone, steroids plus azathioprine, 
or steroids plus rituximab, and that the decrease in PD1+ TFH 
cells was always associated with clinical improvement of the 
disease. Significant variation of TFH cells after treatment with 
steroids has also been recently reported in Japanese patients 
with modification of TFH1 cells, which we did not observe 
in our larger study (29). However, organ involvement was 
significantly different from our study. Interestingly, the PD1+ 
TFH subset  also comprises TFH regulatory cells co-expressing 
Foxp3 and an imbalance of TFH/TFH Foxp3 regulatory could 
also be implicated in the disease’s pathophysiology and should 
be further explored (33).
cOnclUsiOn
We show that patients with active, untreated IgG4-RD presenting 
with variable organ involvements present specific changes of 
T cells in peripheral blood. Circulating PD1+ TFH are expanded 
together with TH2 and TH17, associated with elevated IL-4, 
IL-10, and IL-17 release. Both PD1+ Tfh2 and Tfh17 subsets 
have been shown to be prone to migrate into B  cell follicles 
and/or inflammatory sites and could therefore contribute to 
B cell activation and IgG4 class switch in IgG4-RD tissues. Yet, 
the precise role of these T  cell changes together with the role 
of clonal expanded cytotoxic T  cells, their interactions with 
B  cells and other immune cells, and the induction of fibrosis 
remains to be further assessed in IgG4-RD. Indeed, in a near 
future, it is likely that specific treatments targeting T cells will 
be assessed in IgG4-RD.
aUThOr cOnTribUTiOns
AG, ME, FV, and NS: conception and design of the work; acquisi-
tion, analysis, and interpretation of data for the work; drafting 
the work and revising it critically for important intellectual 
content. CP, CF, J-RH, and NC-C: acquisition, analysis, and 
interpretation of data for the work; revising the work critically 
for important intellectual content. MG, AR, MS, BT, NM, SA, 
FM, JG, MH, AF, SP, EB, and BB: acquisition of data for the work; 
revising the work critically for important intellectual content. All 
authors meet following criteria: final approval of the version to 
9Grados et al. T Cell Polarization in IgG4-RD
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 235
be published and agreement to be accountable for all aspects of 
the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated 
and resolved.
acKnOWleDgMenTs
We thank the patients and healthy controls who participated to 
the study. The authors thank Dr. Frederique Retornaz, Corinne 
Dachary, and Pr. Gilles Kaplanski for the inclusion of healthy 
controls and primary Sjögren syndrome patients.
FUnDing
This study was funded by the French Ministry of Health (PHRC 
IR 2011-31 RC12_3608). The study was also supported by a grant 
from the CSL Behring Company France.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00235/
full#supplementary-material.
reFerences
1. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet (2015) 
385:1460–71. doi:10.1016/S0140-6736(14)60720-0 
2. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, et al. IgG4-related 
systemic disease: features and treatment response in a French cohort: results 
of a multicenter registry. Medicine (Baltimore) (2012) 91:49–56. doi:10.1097/
MD.0b013e3182433d77 
3. Inoue D, Yoshida K, Yoneda N, Ozaki K, Matsubara T, Nagai K, et al. IgG4-
related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 
(2015) 94:e680. doi:10.1097/MD.0000000000000680 
4. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, 
et al. IgG4-related disease: clinical and laboratory features in one hundred 
twenty-five patients. Arthritis Rheumatol (2015) 67:2466–75. doi:10.1002/
art.39205 
5. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et  al. Consensus 
statement on the pathology of IgG4-related disease. Mod Pathol (2012) 
25:1181–92. doi:10.1038/modpathol.2012.72 
6. Morgan WS, Castleman B. A clinicopathologic study of Mikulicz’s disease. 
Am J Pathol (1953) 29:471–503. 
7. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, et al. 
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoprolifer-
ative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum 
Dis (2009) 68:1310–5. doi:10.1136/ard.2008.089169 
8. Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The 
diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann 
Rheum Dis (2015) 74:14–8. doi:10.1136/annrheumdis-2013-204907 
9. Miyake K, Moriyama M, Aizawa K, Nagano S, Inoue Y, Sadanaga A, 
et  al. Peripheral CD4+ T  cells showing a Th2 phenotype in a patient with 
Mikulicz’s disease associated with lymphadenopathy and pleural effusion. 
Mod Rheumatol (2008) 18:86–90. doi:10.1007/s10165-007-0010-3 
10. Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, et al. Autoimmune-
related pancreatitis is associated with autoantibodies and a Th1/Th2-type 
cellular immune response. Gastroenterology (2000) 118:573–81. doi:10.1016/
S0016-5085(00)83803-2 
11. Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, et  al. Th2 
and regulatory immune reactions are increased in immunoglobin G4-related 
sclerosing pancreatitis and cholangitis. Hepatology (2007) 45:1538–46. 
doi:10.1002/hep.21697 
12. Kusuda T, Uchida K, Miyoshi H, Koyabu M, Satoi S, Takaoka M, et  al. 
Involvement of inducible costimulator- and interleukin 10-positive regula-
tory T  cells in the development of IgG4-related autoimmune pancreatitis. 
Pancreas (2011) 40:1120–30. doi:10.1097/MPA.0b013e31821fc796 
13. Koyabu M, Uchida K, Miyoshi H, Sakaguchi Y, Fukui T, Ikeda H, et  al. 
Analysis of regulatory T cells and IgG4-positive plasma cells among patients 
of IgG4-related sclerosing cholangitis and autoimmune liver diseases. 
J Gastroenterol (2010) 45:732–41. doi:10.1007/s00535-010-0199-3 
14. Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, 
et al. Number of circulating follicular helper 2 T cells correlates with IgG4 
and interleukin-4 levels and plasmablast numbers in IgG4-related disease. 
Arthritis Rheumatol (2015) 67:2476–81. doi:10.1002/art.39209 
15. Maruyama M, Watanabe T, Kanai K, Oguchi T, Muraki T, Hamano H, et al. 
International consensus diagnostic criteria for autoimmune pancreatitis and 
its Japanese amendment have improved diagnostic ability over existing crite-
ria. Gastroenterol Res Pract (2013) 2013:456965–8. doi:10.1155/2013/456965 
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and 
powerful approach to multiple testing. J R Statist Soc B (1995) 57(1):289–300.
17. Mattoo H, Mahajan VS, Torre Della E, Sekigami Y, Carruthers M, Wallace 
ZS, et  al. De novo oligoclonal expansions of circulating plasmablasts in 
active and relapsing IgG4-related disease. J Allergy Clin Immunol (2014) 
134:679–87. doi:10.1016/j.jaci.2014.03.034 
18. Zen Y, Liberal R, Nakanuma Y, Heaton N, Portmann B. Possible involve-
ment of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-
related sclerosing cholangitis. J Hepatol (2013) 59:1059–64. doi:10.1016/j.
jhep.2013.06.016 
19. Mattoo H, Mahajan VS, Maehara T, Deshpande V, Torre Della E, Wallace 
ZS, et  al. Clonal expansion of CD4(+) cytotoxic T  lymphocytes in patients 
with IgG4-related disease. J Allergy Clin Immunol (2016) 138:825–38. 
doi:10.1016/j.jaci.2015.12.1330 
20. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and 
its role in autoimmunity. Semin Immunol (2013) 25:305–12. doi:10.1016/j.
smim.2013.10.009 
21. Torre Della E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. 
Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. 
Allergy (2014) 69:269–72. doi:10.1111/all.12320 
22. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg 
S, Haahtela T, et  al. A revised nomenclature for allergy. An EAACI posi-
tion statement from the EAACI nomenclature task force. Allergy (2001) 
56:813–24. doi:10.1111/j.1398-9995.2001.00002.x-i1 
23. Ueno H, Banchereau J, Vinuesa CG. Pathophysiology of T follicular helper 
cells in humans and mice. Nat Immunol (2015) 16:142–52. doi:10.1038/
ni.3054 
24. Schmitt N, Bentebibel S-E, Ueno H. Phenotype and functions of memory 
Tfh cells in human blood. Trends Immunol (2014) 35:436–42. doi:10.1016/j.
it.2014.06.002 
25. Le Coz C, Joublin A, Pasquali J-L, Korganow A-S, Dumortier H, Monneaux 
F. Circulating TFH subset distribution is strongly affected in lupus patients 
with an active disease. PLoS One (2013) 8:e75319. doi:10.1371/journal.
pone.0075319 
26. Morita R, Schmitt N, Bentebibel S-E, Ranganathan R, Bourdery L, Zurawski 
G, et  al. Human blood CXCR5+CD4+ T  cells are counterparts of T follic-
ular cells and contain specific subsets that differentially support antibody 
secretion. Immunity (2011) 34:108–21. doi:10.1016/j.immuni.2010.12.012 
27. Haynes NM, Allen CDC, Lesley R, Ansel KM, Killeen N, Cyster JG. Role 
of CXCR5 and CCR7 in follicular Th cell positioning and appearance of 
a programmed cell death gene-1high germinal center-associated subpop-
ulation. J Immunol (2007) 179:5099–108. doi:10.4049/jimmunol.179.8.5099 
28. Chavele K-M, Merry E, Ehrenstein MR. Cutting edge: circulating plasmab-
lasts induce the differentiation of human T follicular helper cells via IL-6 
production. J Immunol (2015) 194:2482–5. doi:10.4049/jimmunol.1401190 
29. Akiyama M, Yasuoka H, Yamaoka K, Suzuki K, Kaneko Y, Kondo H, et al. 
Enhanced IgG4 production by follicular helper 2 T cells and the involvement 
of follicular helper 1 T  cells in the pathogenesis of IgG4-related disease. 
Arthritis Res Ther (2016) 18:167. doi:10.1186/s13075-016-1064-4 
30. Takeuchi M, Sato Y, Ohno K, Tanaka S, Takata K, Gion Y, et  al. T helper 
2 and regulatory T-cell cytokine production by mast cells: a key factor in 
10
Grados et al. T Cell Polarization in IgG4-RD
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 235
the pathogenesis of IgG4-related disease. Mod Pathol (2014) 27:1126–36. 
doi:10.1038/modpathol.2013.236 
31. Takeuchi M, Ohno K, Takata K, Gion Y, Tachibana T, Orita Y, et al. Interleukin 
13-positive mast cells are increased in immunoglobulin G4-related sialad-
enitis. Sci Rep (2015) 5:7696. doi:10.1038/srep07696 
32. Maehara T, Moriyama M, Nakashima H, Miyake K, Hayashida J-N, Tanaka 
A, et al. Interleukin-21 contributes to germinal centre formation and immu-
noglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, 
so-called Mikulicz’s disease. Ann Rheum Dis (2012) 71:2011–9. doi:10.1136/
annrheumdis-2012-201477 
33. Sage PT, Sharpe AH. T follicular regulatory cells. Immunol Rev (2016) 
271:246–59. doi:10.1111/imr.12411 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Grados, Ebbo, Piperoglou, Groh, Regent, Samson, Terrier, 
Loundou, Morel, Audia, Maurier, Graveleau, Hamidou, Forestier, Palat, Bernit, 
Bonotte, Farnarier, Harlé, Costedoat-Chalumeau, Vély and Schleinitz. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
